Vol 9, No 2 (2024)
Original article
Published online: 2024-05-13

open access

Page views 100
Article views/downloads 4
Get Citation

Connect on Social Media

Connect on Social Media

Impact of fractalkine polymorphisms (rs 614230, rs 170364) on the occurrence of inappropriate body mass

Małgorzata Anna Poręba1, Dorota Puszka1, Agata Macionga1, Paulina Ziółkowska1, Michalina Strzedulla1, Nikola Szweda-Gandor1, Władysław Grzeszczak1
DOI: 10.5603/mrj.99537
Medical Research Journal 2024;9(2):187-191.

Abstract

Introduction: Fractalkine chemokine (CX3CL1) is a protein cytokine which is associated with the pathophysiology of lifestyle-related diseases such as obesity, diabetes and atherosclerosis. This study aimed to assess the influence of fractalkine gene variants (rs 614230, rs 170364) on body mass.

Material and methods: Study group consisted of 295 patients (152 women and 133 men). The blood samples were collected and stored at –70˚C. Afterwards the DNA material was isolated and prepared (quality and quantity were checked by spectrophotometry). Allelic discrimination of fractalkine gene (rs 614230, rs 170364) was performed using Roche Lightcycler96 thermocycler. Real-Time PCR was conducted using fluorescence-labeled TaqMan Pre-designed SNP Genotyping Assay probes.

Results: The CC genotype of fractalkine (rs 614230) had a positive association with BMI compared to CT and TT genotypes. The GG genotype of fractalkine (rs 170364) had a negative association with body size, body mass index and body fat content compared to GT. The TT genotype of fractalkine (rs 170364) shows a negative association with BMI compared to GT.

Conclusions: Fractalkine polymorphism rs 614230 may be associated with high body mass index (BMI), but not with waist size or body fat content. Single nucleotide polymorphisms (SNP) of fractalkine rs 170364 may be associated with high body mass. Further studies in a larger group of patients are necessary to completely assess this association.

Article available in PDF format

View PDF Download PDF file

References

  1. Owłasiuk P, Zajkowska M, Pietruczuk M, et al. Fraktalkina — budowa, właściwości i biologiczna rola. Pol. Merkuriusz Lek. ; 2009: 253–257.
  2. Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol. 2005; 26: 41–47.
  3. Greaves DR, Häkkinen T, Lucas AD, et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001; 21(6): 923–929.
  4. Shah R, Hinkle CC, Ferguson J.F. JF, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011; 60(5): 1512–1518.
  5. Shah R, Hinkle CC, Ferguson JF, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011; 60(5): 1512–1518.
  6. Chan PC, Hsieh PS. The chemokine systems at the crossroads of inflammation and energy metabolism in the development of obesity. Int J Mol Sci. 2021; 22(24).
  7. Schinzari F, Tesauro M, Campia U, et al. Increased fractalkine and vascular dysfunction in obesity and in type 2 diabetes. Effects of oral antidiabetic treatment. .
  8. Demi̇, İ., Guler, A., Alarslan, P. Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. Endocrine. 2019; 65(1): 175–183.
  9. Li W, Chen F, Gao H, et al. Cytokine concentration in peripheral blood of patients with colorectal cancer. Front Immunol. 2023; 14: 1175513.
  10. Nowak M, Janas Ł, Soja M, et al. Chemokine expression in patients with ovarian cancer or benign ovarian tumors. Arch Med Sci. 2022; 18(3): 682–689.
  11. Richter B, Koller L, Hohensinner FJ, et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost. 2012 ; 108(6): 1220–1227.
  12. Zhang X, Feng X, Cai W, et al. Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesion volnerability. Thromb Res. 2015; 135(6): 1147–1153.
  13. Jin SG, Chen GL, Yang SL, et al. Gene-gene interactions among CX3CL1, LEPR and IL-6 related to coronary artery disease in Chinese Han population. Int J Clin Exp Pathol. 2015; 8(5): 5968–5973.
  14. Ibáñez L, Velli PS, Font R, et al. HIV-infection, atherosclerosis and the inflammatory pathway: candidate gene study in a Spanish HIV-infected population. PLoS One 2014;9(11):e112279 Published. ; 2014: Nov 10.
  15. Debette S, Bevan S, Dartigues JF, et al. Fractalkine receptor/ligand genetic variants and carotid intima-media thickness. Stroke. 2009; 40(6): 2212–2214.
  16. Ma G, Yang J, Zhao B, et al. Correlation between CCL2, CALCA, and CX3CL1 gene polymorphisms and chronic pain after cesarean section in Chinese Han women: A case control study. Medicine (Baltimore). 2019; 98(34): e16706.
  17. Sirois-Gagnon D, Chamberland A, Perron S, et al. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity (Silver Spring). 2011 ; 19(1): 222–227.